SANTA CLARA, Calif., Aug. 29 /PRNewswire-FirstCall/ -- XenoPort, Inc. today announced that it will provide access via the world wide web to its Newsmakers in the Biotech Industry presentation. The live presentation will occur at 11:30 a.m. ET on Friday, September 9, 2005. A replay of the presentation will be available for up to one week.
To access the presentation via the web, please go to www.XenoPort.com. Please connect to the company's website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort's most advanced product candidate, XP13512, has successfully completed a Phase 2b clinical trial for the treatment of restless legs syndrome and a Phase 2a clinical trial for the management of post- herpetic neuralgia. XenoPort anticipates commencing Phase 3 clinical trials of XP13512 in RLS patients in the first half of 2006. XenoPort has also completed an initial Phase 1 clinical trial of XP19986, which demonstrated that XP19986 was suitable for twice-a-day dosing and was well tolerated with few adverse events at the doses tested in this clinical trial. XenoPort anticipates commencing additional studies, including a Phase 2a clinical trial of XP19986 in gastroesophageal reflux disease, in the second half of 2005.
To learn more about XenoPort, please visit the web site at www.XenoPort.com.
This press release contains "forward-looking" statements, including, without limitation, all statements related to our future clinical trials for XP13512 and XP19986 and the therapeutic and commercial potential of XP13512 and XP19986. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as, "believes," "anticipates," "plans," "expects," "will," "intends," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort's current expectations. Forward-looking statements involve risks and uncertainties. XenoPort's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability of the company to successfully conduct the clinical trials for XP13512 and XP19986; the ability of the company to advance additional preclinical compounds into clinical development; the uncertainty of the FDA approval process; and the therapeutic and commercial value of the company's compounds. These and other risk factors are discussed under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2005, filed with the Securities and Exchange Commission on August 11, 2005. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: XenoPort is a registered U.S. trademark.
Source code: XPNT2G